All In Biotech

Drug Trial Radar · NCT05265650

Study of BO-112 With Radiotherapy and Nivolumab for Metastatic Refractory NSCLC

Phase Ib/II Open-label Clinical Study of Intratumoral Administration of BO-112 in Combination With Radiotherapy and Nivolumab in Patients With Metastatic PD- 1/PD-L1 Refractory Non-small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Jul 19, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

30

Planned (sponsor's estimate)

Start

Jun 13, 2022

Primary completion

Mar 2024

Study completion Jun 2024

Sponsor

Lead sponsor
Clinica Universidad de Navarra, Universidad de NavarraAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Highlight Therapeutics
First posted
Mar 3, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study of repeated IT administrations of BO-112 in combination with ablative radiotherapy (SABR) and concurrent nivolumab in patients with metastatic PD-1/PD-L1-refractory NSCLC.

Conditions

  • Non-Small Cell Lung Cancer Metastatic

Interventions

  • BO-112 in combination with ablative radiotherapy (SABR) and nivolumabDrug

    Study treatment will consist of BO-112 IT injections in combination with IV nivolumab infusions and SABR to accessible metastases.

  • Tissue BiopsiesProcedure

    Four research biopsies will be taken from accessible injected lesions, at the time of the IT injection of BO-112.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse events and Serious Adverse EventsTime frame: Throughout study completion, an average of 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Clínica Universidad de Navarra

    Pamplona, Navarre, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.